Cargando…
Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) showed great value in treating nonalcoholic fatty liver disease (NAFLD). We aimed to compare the effectiveness of long-acting and short-acting GLP-1RAs on improving body weight and related metabolic parameters in patients with type 2 d...
Autores principales: | Yuan, Xia, Gao, Zhe, Hao, Zhihua, Ma, Huijuan, Duan, Kaixin, Yang, Caixuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615555/ https://www.ncbi.nlm.nih.gov/pubmed/37904378 http://dx.doi.org/10.1097/MD.0000000000035739 |
Ejemplares similares
-
Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report
por: Terakawa, Aiko, et al.
Publicado: (2020) -
Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis
por: Chen, Han, et al.
Publicado: (2023) -
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015) -
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis
por: Qiu, Mei, et al.
Publicado: (2020) -
Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
por: Guo, Lixin, et al.
Publicado: (2015)